Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases

Cariprazine is a novel antipsychotic drug that exerts partial agonism of dopamine D(2)/D(3) receptors with preferential binding to the D(3) receptor, antagonism of 5HT(2B) receptors, and partial agonism of 5HT(1A). Currently, cariprazine has shown clinical efficacy in patients with schizophrenia and...

Descripción completa

Detalles Bibliográficos
Autores principales: Berardis, Domenico De, Rapini, Gabriella, Olivieri, Luigi, Giardini, Agostina, Lauretis, Ida De, Serroni, Nicola, Orsolini, Laura, Fornaro, Michele, Iasevoli, Felice, Trotta, Sabatino, Cottura, Paolo, Vellante, Federica, Alessandrini, Marco, Giannantonio, Massimo Di
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean College of Neuropsychopharmacology 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851462/
https://www.ncbi.nlm.nih.gov/pubmed/33508803
http://dx.doi.org/10.9758/cpn.2021.19.1.174
Descripción
Sumario:Cariprazine is a novel antipsychotic drug that exerts partial agonism of dopamine D(2)/D(3) receptors with preferential binding to the D(3) receptor, antagonism of 5HT(2B) receptors, and partial agonism of 5HT(1A). Currently, cariprazine has shown clinical efficacy in patients with schizophrenia and with bipolar disorder, as well as adjunctive treatment in patients with Major Depressive Disorder (MDD) and drug-resistant MDD. In the present case series, we report on two patients with treatment-resistant schizophrenia and partial response to clozapine who benefit from combination with cariprazine. The effects of cariprazine combination were remarkable also concerning the adverse metabolic effects of clozapine.

Ejemplares similares